These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Nikolaus S; Fölscn U; Schreiber S Hepatogastroenterology; 2000; 47(31):71-82. PubMed ID: 10690587 [TBL] [Abstract][Full Text] [Related]
10. [Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH]. Dejaco C; Haas T; Kirchgatterer A; Miehsler W; Wenzl H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W; Tilg H Z Gastroenterol; 2006 Jun; 44(6):525-38; discussion 539. PubMed ID: 16773519 [TBL] [Abstract][Full Text] [Related]
11. [Changing treatment of inflammatory bowel diseases]. Karvonen AL; Matikainen M; Turunen U Duodecim; 1994; 110(20):1945-54. PubMed ID: 7555809 [No Abstract] [Full Text] [Related]
12. [5-ASA versus sulfasalazine]. Varela E Acta Gastroenterol Latinoam; 1994; 25(5):317-9. PubMed ID: 7785405 [No Abstract] [Full Text] [Related]
20. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Hanauer SB; Stathopoulos G Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]